{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:47:37Z","timestamp":1792086457029,"version":"4.4.0"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T00:00:00Z","timestamp":1560988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009776","name":"McMaster University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009776","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Biomaterialia"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.actbio.2019.06.021","type":"journal-article","created":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T11:27:45Z","timestamp":1560857265000},"page":"2-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":252,"special_numbering":"C","title":["The blood compatibility challenge. Part 1: Blood-contacting medical devices: The scope of the problem"],"prefix":"10.1016","volume":"94","author":[{"given":"Iqbal H.","family":"Jaffer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Weitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.actbio.2019.06.021_b0005","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/cid\/cir138","article-title":"Summary of recommendations: guidelines for the prevention of intravascular catheter-related infections","volume":"52","author":"O'Grady","year":"2011","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"issue":"12","key":"10.1016\/j.actbio.2019.06.021_b0010","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJMra011883","article-title":"Preventing complications of central venous catheterization","volume":"348","author":"McGee","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.actbio.2019.06.021_b0015","doi-asserted-by":"crossref","unstructured":"F.M. Insights, Central Venous Catheter Market: Non-tunnelled Catheters Expected to Dominate the Market Through 2026: Global Industry Analysis and Opportunity Assessment, 2016-2026. https:\/\/www.futuremarketinsights.com\/reports\/central-venous-catheter-market. (accessed 07\/09\/2017).","DOI":"10.1016\/j.focat.2016.12.004"},{"issue":"Complete","key":"10.1016\/j.actbio.2019.06.021_b0020","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.thromres.2017.07.002","article-title":"Epidemiology, diagnosis, prevention and treatment of catheter-related thrombosis in children and adults","volume":"157","author":"Baumann Kreuziger","year":"2017","journal-title":"Thromb. Res."},{"issue":"11","key":"10.1016\/j.actbio.2019.06.021_b0025","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1016\/j.actbio.2012.07.019","article-title":"Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in vitro and in vivo","volume":"8","author":"Yau","year":"2012","journal-title":"Acta Biomater."},{"issue":"3","key":"10.1016\/j.actbio.2019.06.021_b0030","doi-asserted-by":"crossref","DOI":"10.1088\/1748-6041\/3\/3\/034003","article-title":"Biofilm formation, bacterial adhesion and host response on polymeric implants\u2014issues and prevention","volume":"3","author":"Pavithra","year":"2008","journal-title":"Biomed. Mater."},{"issue":"8","key":"10.1016\/j.actbio.2019.06.021_b0035","first-page":"588","article-title":"Is direct stenting superior to stenting with predilation in patients treated with percutaneous coronary intervention? results from a meta-analysis of 24 randomised controlled trials","volume":"96","author":"Piscione","year":"2010","journal-title":"Heart (British Cardiac Soc.)"},{"issue":"1","key":"10.1016\/j.actbio.2019.06.021_b0040","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ijcard.2014.04.269","article-title":"Trend in the use of drug eluting stents in the United States","volume":"175","author":"Bangalore","year":"2014","journal-title":"Int. J. Cardiol."},{"issue":"1","key":"10.1016\/j.actbio.2019.06.021_b0045","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1055\/s-0037-1606178","article-title":"Stent thrombosis","volume":"44","author":"Gopalakrishnan","year":"2018","journal-title":"Semin. Thromb. Hemost."},{"issue":"2","key":"10.1016\/j.actbio.2019.06.021_b0050","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11886-018-0952-4","article-title":"Therapeutic options for in-stent restenosis","volume":"20","author":"Nicolais","year":"2018","journal-title":"Curr. Cardiol. Reports"},{"issue":"4","key":"10.1016\/j.actbio.2019.06.021_b0055","doi-asserted-by":"crossref","first-page":"518","DOI":"10.23736\/S0021-9509.17.09946-3","article-title":"Optical coherence tomography: guided therapy of in-stent restenosis for peripheral arterial disease","volume":"58","author":"Lichtenberg","year":"2017","journal-title":"J. Cardiovasc. Surg."},{"key":"10.1016\/j.actbio.2019.06.021_b0060","unstructured":"U.C.f.D.C.a. Prevention, Cost of hospital discharges with common hospital operating room procedures by age and selected principal procedure, 2016. https:\/\/www.cdc.gov\/nchs\/fastats\/heart-disease.htm. (accessed 07\/09\/2017)."},{"key":"10.1016\/j.actbio.2019.06.021_b0065","unstructured":"ResearchandMarkets.com, 2018 Aortic Valve Market by Product, by Procedure, by End User, by Geography - Global Market Size, Share, Development, Growth, and Demand Forecast, 2013-2023, 2019. https:\/\/www.globenewswire.com\/news-release\/2019\/02\/12\/1720819\/0\/en\/2018-Aortic-Valve-Market-by-Product-by-Procedure-by-End-User-by-Geography-Global-Market-Size-Share-Development-Growth-and-Demand-Forecast-2013-2023.html. (accessed 04\/04\/2019)."},{"issue":"25","key":"10.1016\/j.actbio.2019.06.021_b0070","doi-asserted-by":"crossref","first-page":"e1159","DOI":"10.1161\/CIR.0000000000000503","article-title":"2017 AHA\/ACC focused update of the 2014 AHA\/ACC guideline for the management of patients with valvular heart disease: a report of the american college of cardiology\/american heart association task force on clinical practice guidelines","volume":"135","author":"Nishimura","year":"2017","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.actbio.2019.06.021_b0075","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/eurheartj\/ehy590","article-title":"Outcomes of transcatheter mitral valve replacement for degenerated bioprostheses, failed annuloplasty rings, and mitral annular calcification","volume":"40","author":"Yoon","year":"2019","journal-title":"Eur. Heart J."},{"issue":"11","key":"10.1016\/j.actbio.2019.06.021_b0080","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.jacc.2018.12.065","article-title":"Percutaneous transcatheter mitral valve replacement: first-in-human experience with a new transseptal system","volume":"73","author":"Webb","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"28","key":"10.1016\/j.actbio.2019.06.021_b0085","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1093\/eurheartj\/ehy107","article-title":"Annual number of candidates for transcatheter aortic valve implantation per country: current estimates and future projections","volume":"39","author":"Durko","year":"2018","journal-title":"Eur. Heart J."},{"issue":"8","key":"10.1016\/j.actbio.2019.06.021_b0090","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002322","article-title":"Dabigatran is less effective than warfarin at attenuating mechanical heart valve-induced thrombin generation","volume":"4","author":"Jaffer","year":"2015","journal-title":"J. Am. Heart Assoc."},{"issue":"4","key":"10.1016\/j.actbio.2019.06.021_b0095","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/00002216-199010000-00006","article-title":"Effective endothelialization of polyurethane surfaces. Response to shear stress and platelet adhesion","volume":"36","author":"Zhu","year":"1990","journal-title":"ASAIO Trans."},{"issue":"24","key":"10.1016\/j.actbio.2019.06.021_b0100","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1016\/j.jacc.2016.09.958","article-title":"Prosthetic heart valve thrombosis","volume":"68","author":"Dangas","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"issue":"22","key":"10.1016\/j.actbio.2019.06.021_b0105","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1016\/j.jacc.2016.03.506","article-title":"3-Year outcomes in high-risk patients who underwent surgical or transcatheter aortic valve replacement","volume":"67","author":"Deeb","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.actbio.2019.06.021_b0110","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ahj.2016.10.017","article-title":"Trial design: rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: rationale and design of the GALILEO study","volume":"184","author":"Windecker","year":"2017","journal-title":"Am. Heart J."},{"key":"10.1016\/j.actbio.2019.06.021_b0115","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ahj.2018.03.008","article-title":"Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: the randomized ATLANTIS trial","volume":"200","author":"Collet","year":"2018","journal-title":"Am. Heart J."},{"key":"10.1016\/j.actbio.2019.06.021_b0120","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ahj.2018.07.006","article-title":"Edoxaban Versus standard of care and their effects on clinical outcomes in patients having undergone transcatheter aortic valve implantation in atrial fibrillation-rationale and design of the ENVISAGE-TAVI AF trial","volume":"205","author":"Van Mieghem","year":"2018","journal-title":"Am. Heart J."},{"key":"10.1016\/j.actbio.2019.06.021_b0125","unstructured":"T. Neale, GALILEO Trial of Rivaroxaban After TAVR Stopped Early for Harm, 2018. https:\/\/www.tctmd.com\/news\/galileo-trial-rivaroxaban-after-tavr-stopped-early-harm. (accessed 07\/06\/2019)."},{"issue":"1","key":"10.1016\/j.actbio.2019.06.021_b0130","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2014-000109","article-title":"Trends in left ventricular assist device use and outcomes among Medicare beneficiaries, 2004\u20132011","volume":"1","author":"Lampropulos","year":"2014","journal-title":"Open Heart"},{"issue":"6","key":"10.1016\/j.actbio.2019.06.021_b0135","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/jth.12948","article-title":"Antithrombotic therapy for left ventricular assist devices in adults: a systematic review","volume":"13","author":"Baumann Kreuziger","year":"2015","journal-title":"J. Thrombosis Haemostasis"},{"issue":"1","key":"10.1016\/j.actbio.2019.06.021_b0140","first-page":"674","article-title":"Anticoagulation with VADs and ECMO: walking the tightrope","volume":"2017","author":"Raffini","year":"2017","journal-title":"Hematology (Amsterdam, Netherlands)"},{"issue":"2","key":"10.1016\/j.actbio.2019.06.021_b0145","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/HCO.0000000000000143","article-title":"Anticoagulation strategies for left ventricular assist devices","volume":"30","author":"Toeg","year":"2015","journal-title":"Curr. Opin. Cardiol."},{"issue":"3","key":"10.1016\/j.actbio.2019.06.021_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtcvs.2013.12.047","article-title":"Trends in use of off-pump coronary artery bypass grafting: results from the society of thoracic surgeons adult cardiac surgery database","volume":"148","author":"Bakaeen","year":"2014","journal-title":"J. Thoracic Cardiovasc. Surg."},{"issue":"1","key":"10.1016\/j.actbio.2019.06.021_b0155","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1186\/s13054-015-1155-7","article-title":"Extracorporeal membrane oxygenation (ECMO) for critically ill adults in the emergency department: history, current applications, and future directions","volume":"19","author":"Mosier","year":"2015","journal-title":"Crit. Care"},{"key":"10.1016\/j.actbio.2019.06.021_b0160","unstructured":"E.L.S.O. (ELS)), ECLS Registry Report - International Summary July 2017, 2017. https:\/\/www.elso.org\/Registry\/Statistics.aspx."},{"issue":"1\u20132","key":"10.1016\/j.actbio.2019.06.021_b0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/ten.2005.11.1","article-title":"Mediation of biomaterial-cell interactions by adsorbed proteins: a review","volume":"11","author":"Wilson","year":"2005","journal-title":"Tissue Eng."},{"issue":"24","key":"10.1016\/j.actbio.2019.06.021_b0170","doi-asserted-by":"crossref","first-page":"6157","DOI":"10.1016\/j.biomaterials.2014.04.012","article-title":"Effect of the interplay between protein and surface on the properties of adsorbed protein layers","volume":"35","author":"Ouberai","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.actbio.2019.06.021_b0175","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.chroma.2014.12.087","article-title":"Protein behavior at surfaces: orientation, conformational transitions and transport","volume":"1382","author":"Yu","year":"2015","journal-title":"J. Chromatogr. A"},{"issue":"13","key":"10.1016\/j.actbio.2019.06.021_b0180","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0142-9612(96)80004-4","article-title":"Proteins involved in the Vroman effect during exposure of human blood plasma to glass and polyethylene","volume":"17","author":"Turbill","year":"1996","journal-title":"Biomaterials"},{"issue":"1\u20133","key":"10.1016\/j.actbio.2019.06.021_b0185","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0142-9612(97)00206-8","article-title":"Stagnant versus dynamic conditions: a comparative adsorption study of blood proteins","volume":"19","author":"Ortega-Vinuesa","year":"1998","journal-title":"Biomaterials"},{"issue":"26","key":"10.1016\/j.actbio.2019.06.021_b0190","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1016\/j.biomaterials.2004.01.023","article-title":"Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes","volume":"25","author":"Gorbet","year":"2004","journal-title":"Biomaterials"},{"issue":"17","key":"10.1016\/j.actbio.2019.06.021_b0195","doi-asserted-by":"crossref","first-page":"11227","DOI":"10.1016\/S0021-9258(18)99152-0","article-title":"Selective recognition of adhesive sites in surface-bound fibrinogen by glycoprotein IIb-IIIa on nonactivated platelets","volume":"266","author":"Savage","year":"1991","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.actbio.2019.06.021_b0200","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/(SICI)1097-4636(199902)44:2<130::AID-JBM2>3.0.CO;2-9","article-title":"Human plasma fibrinogen adsorption and platelet adhesion to polystyrene","volume":"44","author":"Tsai","year":"1999","journal-title":"J. Biomed. Mater. Res."},{"issue":"3","key":"10.1016\/j.actbio.2019.06.021_b0205","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/jbm.10048","article-title":"Platelet adhesion to polystyrene-based surfaces preadsorbed with plasmas selectively depleted in fibrinogen, fibronectin, vitronectin, or von Willebrand's factor","volume":"60","author":"Tsai","year":"2002","journal-title":"J. Biomed. Mater. Res."},{"issue":"3","key":"10.1016\/j.actbio.2019.06.021_b0210","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1055\/s-0035-1564835","article-title":"Platelet physiology","volume":"42","author":"Gremmel","year":"2016","journal-title":"Semin. Thromb. Hemost."},{"issue":"1","key":"10.1016\/j.actbio.2019.06.021_b0215","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1476-4431.2009.00389.x","article-title":"The cell-based model of coagulation","volume":"19","author":"Smith","year":"2009","journal-title":"J. Vet. Emerg. Crit. Care (San Antonio, Tex: 2001)"},{"issue":"2","key":"10.1016\/j.actbio.2019.06.021_b0220","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00109-010-0691-5","article-title":"Platelet receptor signaling in thrombus formation","volume":"89","author":"Stegner","year":"2011","journal-title":"J. Mol. Med. (Berlin, Germany)"},{"key":"10.1016\/j.actbio.2019.06.021_b0225","series-title":"Platelets","article-title":"The regulation of platelet life span","author":"Josefsson","year":"2013"},{"issue":"27","key":"10.1016\/j.actbio.2019.06.021_b0230","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1016\/j.biomaterials.2009.05.044","article-title":"Blood coagulation on biomaterials requires the combination of distinct activation processes","volume":"30","author":"Sperling","year":"2009","journal-title":"Biomaterials"},{"issue":"Suppl 1","key":"10.1016\/j.actbio.2019.06.021_b0235","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/j.thromres.2014.03.018","article-title":"Physiologic activities of the contact activation system","volume":"133","author":"Schmaier","year":"2014","journal-title":"Thromb. Res."},{"issue":"1","key":"10.1016\/j.actbio.2019.06.021_b0240","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/jth.13194","article-title":"The contact activation and kallikrein\/kinin systems: pathophysiologic and physiologic activities","volume":"14","author":"Schmaier","year":"2016","journal-title":"J. Thromb. Haemostasis"},{"issue":"222","key":"10.1016\/j.actbio.2019.06.021_b0245","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3006804","article-title":"A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk","volume":"6","author":"Larsson","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"11","key":"10.1016\/j.actbio.2019.06.021_b0250","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood-2013-04-499111","article-title":"Factor XII inhibition reduces thrombus formation in a primate thrombosis model","volume":"123","author":"Matafonov","year":"2014","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.actbio.2019.06.021_b0255","doi-asserted-by":"crossref","first-page":"6667","DOI":"10.1182\/blood-2011-07-364141","article-title":"Mechanism of catheter thrombosis: comparison of the antithrombotic activities of fondaparinux, enoxaparin, and heparin in vitro and in vivo","volume":"118","author":"Yau","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.actbio.2019.06.021_b0260","unstructured":"R.J. Johnson, Complement activation during extracorporeal therapy: biochemistry, cell biology and clinical relevance, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 9 Suppl 2 (1994) 36-45."},{"key":"10.1016\/j.actbio.2019.06.021_b0265","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-1-4684-5718-6_3","article-title":"Mechanisms and consequences of complement activation during hemodialysis","volume":"260","author":"Kazatchkine","year":"1989","journal-title":"Adv. Exp. Med. Biol."},{"issue":"10","key":"10.1016\/j.actbio.2019.06.021_b0270","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.imbio.2016.06.005","article-title":"Complement-coagulation crosstalk on cellular and artificial surfaces","volume":"221","author":"Wiegner","year":"2016","journal-title":"Immunobiology"},{"key":"10.1016\/j.actbio.2019.06.021_b0275","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3389\/fmed.2018.00352","article-title":"Current understanding of how extracorporeal membrane oxygenators activate haemostasis and other blood components","volume":"5","author":"Doyle","year":"2018","journal-title":"Front. Med."},{"key":"10.1016\/j.actbio.2019.06.021_b0280","series-title":"Immune Responses to Biosurfaces","first-page":"77","article-title":"The lectin pathway of complement and biocompatibility","author":"Hein","year":"2015"},{"issue":"8","key":"10.1016\/j.actbio.2019.06.021_b0285","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1182\/blood-2012-02-412080","article-title":"Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway","volume":"120","author":"Krisinger","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.actbio.2019.06.021_b0290","series-title":"Current Topics in Complement II","first-page":"68","article-title":"Interaction between the coagulation and complement system","author":"Amara","year":"2008"},{"issue":"2","key":"10.1016\/j.actbio.2019.06.021_b0295","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jbiomech.2012.11.033","article-title":"Device thrombogenicity emulation: a novel methodology for optimizing the thromboresistance of cardiovascular devices","volume":"46","author":"Bluestein","year":"2013","journal-title":"J. Biomech."},{"issue":"20","key":"10.1016\/j.actbio.2019.06.021_b0300","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.actbio.2019.06.021_b0305","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"9990","key":"10.1016\/j.actbio.2019.06.021_b0310","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0140-6736(15)60213-6","article-title":"Clinical evidence for oral antiplatelet therapy in acute coronary syndromes","volume":"386","author":"Wiviott","year":"2015","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.actbio.2019.06.021_b0315","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1056\/NEJM199106273242606","article-title":"Oral anticoagulant drugs","volume":"324","author":"Hirsh","year":"1991","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.actbio.2019.06.021_b0320","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199105303242206","article-title":"Heparin","volume":"324","author":"Hirsh","year":"1991","journal-title":"N. Engl. J. Med."},{"issue":"4 Supplement","key":"10.1016\/j.actbio.2019.06.021_b0325","doi-asserted-by":"crossref","first-page":"258S","DOI":"10.1378\/chest.108.4_Supplement.258S","article-title":"Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety","volume":"108","author":"Hirsh","year":"1995","journal-title":"Chest"},{"issue":"10","key":"10.1016\/j.actbio.2019.06.021_b0330","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJM199709043371007","article-title":"Low-molecular-weight heparins","volume":"337","author":"Weitz","year":"1997","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.actbio.2019.06.021_b0335","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/jama.295.13.joc60038","article-title":"Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial","volume":"295","author":"Yusuf","year":"2006","journal-title":"J. Am. Med. Assoc."},{"issue":"5","key":"10.1016\/j.actbio.2019.06.021_b0340","first-page":"795","article-title":"Protamine neutralization of intravenous and subcutaneous low-molecular-weight heparin (tinzaparin, Logiparin). An experimental investigation in healthy volunteers, Blood coagulation & fibrinolysis","volume":"5","author":"Holst","year":"1994","journal-title":"Int. J. Haemostasis Thromb."},{"issue":"3","key":"10.1016\/j.actbio.2019.06.021_b0345","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1213\/00000539-198503000-00008","article-title":"Protamine: a review of its toxicity","volume":"64","author":"Horrow","year":"1985","journal-title":"Anesth. Analg."},{"issue":"7","key":"10.1016\/j.actbio.2019.06.021_b0350","first-page":"565","article-title":"Protamine reversal of low molecular weight heparin: clinically effective? Blood coagulation & fibrinolysis","volume":"22","author":"van Veen","year":"2011","journal-title":"Int. J. Haemostasis Thromb."},{"issue":"Supplement 2","key":"10.1016\/j.actbio.2019.06.021_b0355","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S0049-3848(10)70147-X","article-title":"Factor Xa and thrombin as targets for new oral anticoagulants","volume":"127","author":"Weitz","year":"2011","journal-title":"Thromb. Res."},{"issue":"3","key":"10.1016\/j.actbio.2019.06.021_b0360","doi-asserted-by":"crossref","first-page":"V275","DOI":"10.1016\/S0049-3848(02)00093-2","article-title":"Direct thrombin inhibitors","volume":"106","author":"Weitz","year":"2002","journal-title":"Thromb. Res."},{"key":"10.1016\/j.actbio.2019.06.021_b0365","doi-asserted-by":"crossref","unstructured":"J.I. Weitz, J.W. Eikelboom, M.M. Samama, New antithrombotic drugs: Antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians evidence-based clinical practice guidelines, Chest 141(2_suppl) (2012) e120S-e151S.","DOI":"10.1378\/chest.11-2294"},{"issue":"2","key":"10.1016\/j.actbio.2019.06.021_b0370","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11239-019-01806-z","article-title":"Patterns in anticoagulant utilization in the Czech Republic during 2007\u20132017","volume":"47","author":"Maly","year":"2019","journal-title":"J. Thromb. Thromb."},{"issue":"9","key":"10.1016\/j.actbio.2019.06.021_b0375","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012023","article-title":"Changes in anticoagulant utilization among United States nursing home residents with atrial fibrillation from 2011 to 2016","volume":"8","author":"Alcusky","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.actbio.2019.06.021_b0380","unstructured":"U.S.F.a.D.A. (USFDA), FDA Drug Safety Communication: Pradaxa (dabigatran etexilate meylate) should not be used in patients with mechanical prosthetic heart valves, 2013. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm332912.htm. (accessed 25\/03\/ 2015)."},{"issue":"4","key":"10.1016\/j.actbio.2019.06.021_b0385","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/ejh.13208","article-title":"The efficacy and safety of direct oral anticoagulants in patients with chronic renal insufficiency: a review of the literature","volume":"102","author":"Weber","year":"2019","journal-title":"Eur. J. Haematol."},{"issue":"8","key":"10.1016\/j.actbio.2019.06.021_b0390","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0161768","article-title":"Risk of ischemic stroke, hemorrhagic stroke, bleeding, and death in patients switching from vitamin k antagonist to dabigatran after an ablation","volume":"11","author":"Pallisgaard","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.actbio.2019.06.021_b0395","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1177\/1941874415569069","article-title":"Dabigatran-associated intracranial hemorrhage: literature review and institutional experience","volume":"5","author":"King","year":"2015","journal-title":"Neurohospitalist"},{"issue":"13","key":"10.1016\/j.actbio.2019.06.021_b0400","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1182\/blood-2013-12-540872","article-title":"Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits","volume":"123","author":"Yau","year":"2014","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.actbio.2019.06.021_b0405","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1111\/j.1538-7836.2010.04031.x","article-title":"Coagulation factor XI as a novel target for antithrombotic treatment","volume":"8","author":"Lowenberg","year":"2010","journal-title":"J. Thromb. Haemostasis"},{"issue":"1","key":"10.1016\/j.actbio.2019.06.021_b0410","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1128\/IAI.05568-11","article-title":"Factor XI-deficient mice display reduced inflammation, coagulopathy, and bacterial growth during listeriosis","volume":"80","author":"Luo","year":"2012","journal-title":"Infect. Immun."},{"issue":"3","key":"10.1016\/j.actbio.2019.06.021_b0415","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"B\u00fcller","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.actbio.2019.06.021_b0420","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/707863","article-title":"Surface modification of biomaterials: a quest for blood compatibility","volume":"2012","author":"de Mel","year":"2012","journal-title":"Int. J. Biomater."},{"issue":"11","key":"10.1016\/j.actbio.2019.06.021_b0425","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1016\/j.actbio.2011.06.051","article-title":"Small calibre polyhedral oligomeric silsesquioxane nanocomposite cardiovascular grafts: influence of porosity on the structure, haemocompatibility and mechanical properties","volume":"7","author":"Ahmed","year":"2011","journal-title":"Acta Biomater."},{"issue":"11","key":"10.1016\/j.actbio.2019.06.021_b0430","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1002\/jbm.a.35818","article-title":"PCL films of varying porosity influence ICAM-1 expression of HUVECs","volume":"104","author":"Hu","year":"2016","journal-title":"J. Biomed. Mater. Res. Part A"},{"issue":"1","key":"10.1016\/j.actbio.2019.06.021_b0435","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1021\/acs.biomac.6b01770","article-title":"Combining electrospun fiber mats and bioactive coatings for vascular graft prostheses","volume":"18","author":"Savoji","year":"2017","journal-title":"Biomacromolecules"},{"issue":"11","key":"10.1016\/j.actbio.2019.06.021_b0440","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1021\/bm800681k","article-title":"Biofunctionalization of biomaterials for accelerated in situ endothelialization: a review","volume":"9","author":"de Mel","year":"2008","journal-title":"Biomacromolecules"},{"issue":"4","key":"10.1016\/j.actbio.2019.06.021_b0445","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1021\/la203821g","article-title":"Modification of polyurethane surface with an antithrombin-heparin complex for blood contact: influence of molecular weight of polyethylene oxide used as a linker\/spacer","volume":"28","author":"Sask","year":"2012","journal-title":"Langmuir ACS J. Surfaces Colloids"},{"issue":"1","key":"10.1016\/j.actbio.2019.06.021_b0450","doi-asserted-by":"crossref","first-page":"11639","DOI":"10.1038\/s41598-017-12149-1","article-title":"An omniphobic lubricant-infused coating produced by chemical vapor deposition of hydrophobic organosilanes attenuates clotting on catheter surfaces","volume":"7","author":"Badv","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.actbio.2019.06.021_b0455","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1038\/ncomms3168","article-title":"Bio-responsive polymer hydrogels homeostatically regulate blood coagulation","volume":"4","author":"Maitz","year":"2013","journal-title":"Nat. Commun."},{"issue":"45","key":"10.1016\/j.actbio.2019.06.021_b0460","doi-asserted-by":"crossref","first-page":"1703934","DOI":"10.1002\/adfm.201703934","article-title":"Thrombosis-responsive thrombolytic coating based on thrombin-degradable tissue plasminogen activator (t-PA) nanocapsules","volume":"27","author":"Li","year":"2017","journal-title":"Adv. Funct. Mater."}],"container-title":["Acta Biomaterialia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706119304325?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706119304325?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T17:26:18Z","timestamp":1761672378000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1742706119304325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":92,"alternative-id":["S1742706119304325"],"URL":"https:\/\/doi.org\/10.1016\/j.actbio.2019.06.021","relation":{},"ISSN":["1742-7061"],"issn-type":[{"value":"1742-7061","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The blood compatibility challenge. Part 1: Blood-contacting medical devices: The scope of the problem","name":"articletitle","label":"Article Title"},{"value":"Acta Biomaterialia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actbio.2019.06.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd on behalf of Acta Materialia Inc.","name":"copyright","label":"Copyright"}]}}